Treatment for Diabetes Mellitus, Type 2

Waitlist Available · 18+ · All Sexes · Wilmington, NC

This study is evaluating the safety of the Eversense CGM system.

See full description

About the trial for Diabetes Mellitus, Type 2

Eligible Conditions
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Diabetes Mellitus

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Subject has diabetes
Subject is greater than 18 years of age
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 2 primary outcomes in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of 12 months.

Incidence of procedure-related adverse events
The primary safety endpoint is the Incidence of the composite of infection, secondary procedures to remove the sensor, or procedure-related adverse events of at least moderate severity
Time in Range
The primary effectiveness endpoint is Time in Range, which is defined as glucose values between 70mg/dL and 180 mg/dL, at 12 months post first sensor insertion compared to first month post first sensor insertion

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for diabetes mellitus, type 2?

Diabetes is frequently treated through diet, exercise, or medication, but many people also use other modalities, such as surgical procedures, endovascular treatments, and pharmaceutical therapies.

Anonymous Patient Answer

Does treatment improve quality of life for those with diabetes mellitus, type 2?

The treatment of Type 2 diabetes mellitus may improve some aspects of quality of life for patients. However, the majority of patients did not report improvement in either of the five QoL domains.

Anonymous Patient Answer

What does treatment usually treat?

Clinical practice should focus on the early detection and treatment of vascular and retinal microvascular problems in patients with diabetes, not on the treatment of non-vascular conditions. Clinicians should adopt the concept of a 'treat-target-treat' approach instead of the traditional 'treat-treat-treat' approach.

Anonymous Patient Answer

What are the signs of diabetes mellitus, type 2?

Signs of diabetes mellitus, type 2 can be readily identifiable and may occur prior to diagnosis. In addition to the classic symptoms and signs of diabetes mellitus, such as hyperglycaemia, diabetes ketoacidosis and a random glucose measurement, signs of microalbuminuria can also be present.

Anonymous Patient Answer

How many people get diabetes mellitus, type 2 a year in the United States?

There will be around 382,000 to 3,930,000 new cases of prediabetes, accounting for a 21.3%-53.8% prevalence in the US over the next 10 years. Diabetes was diagnosed in nearly 3.8 million (14.5% of the total population) in 2015. Diabetes accounted for about 11% of all cases of diabetes in 2015 in the US. Diabetic adults had higher annual expenditure for health than non-diabetic adults per year, both in total and for specific service utilization.

Anonymous Patient Answer

What is diabetes mellitus, type 2?

Diabetes mellitus, type 2 (DM-2) is a major chronic metabolic disease worldwide. It is a major risk factor for heart disease, stroke, and blindness. DM-2 is characterized by impaired glucose tolerance or impaired fasting glucose and by chronic hyperglycemia or high blood glucose. In many developing countries, and particularly in Africa, DM-2 is the leading cause of diabetes-associated morbidities and mortality, causing an enormous global burden.

Anonymous Patient Answer

Can diabetes mellitus, type 2 be cured?

With adequate care, the long-term prognosis for type 2 diabetes can be excellent. However, people with type 2 diabetes suffer an increased mortality rate, and most of their life spans are wasted.

Anonymous Patient Answer

What causes diabetes mellitus, type 2?

Diabetes mellitus, type 2, is a complex disease that has more than one etiological factor. Insulin resistance, the inability of the body to control blood sugar levels properly, appears to be a cause of this condition in 20%-25% of patients. Other causes of insulin resistance include obesity, aging, and decreased insulin sensitivity of the peripheral tissues such as those of the liver. Poor blood sugar control may be the result of an unknown combination of hereditary and acquired factors.

Anonymous Patient Answer

What is treatment?

[Diabetes mellitus, type 2 is a chronic disease that is hard to reverse unless it is addressed and well controlled. Most patients do not have a target lifestyle or medication regimen that will help prevent this disease's progress and manage symptoms. However, lifestyle changes, medication, or both may reduce risks of complications of the disease, such as cardiovascular disease(heart disease and stroke), poor blood sugar and blood pressure control, amputations/foot ulcers, and vision loss. To manage [DMT2], patients can find treatments available from many [sources, including healthcare providers in your area, your caregiver, and from the American Diabetes Association at our website's support page.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

Results from a recent paper, we identified that the use of medications for diabetes with anticytokine agents significantly improved survival in patients with diabetes compared with placebo, but not in patients with diabetes without anticytokine agents. Further investigation into possible mechanisms for this finding is warranted.

Anonymous Patient Answer

Who should consider clinical trials for diabetes mellitus, type 2?

The presence of diabetes mellitus, type 2, does not necessarily increase the likelihood of presenting with atherogenic lipids or endothelial dysfunction. In an Asian population, there does seem to be a higher likelihood of diabetic patients with dyslipidemia, however, dyslipidemia does occur in diabetic mellitus, type 2, patients and is related to certain pathogenic factors. There is a lack of clinical evidence to support the use of any dietary, pharmacologic, or exercise treatments for dyslipidemia in diabetes mellitus, type 2.

Anonymous Patient Answer

Does diabetes mellitus, type 2 run in families?

Recent findings provide evidence that diabetes mellitus type 2 runs in families and that a single (or even a multiple) gene is responsible for the disease.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Diabetes Mellitus, Type 2 by sharing your contact details with the study coordinator.